Celgene’s Multiple Myeloma Drugs Secures NICE Recommendation
The UK’s National Institute for Health and Care Excellence (NICE) has changed its mind on a previous decision not to recommend Celgene’s Revlimid (lenalidomide) as a maintenance treatment for certain newly diagnosed multiple myeloma patients, giving the blockbuster chemotherapy drug the thumbs up for use by the National Health Service (NHS).
Specifically, the institute has recommended the drug as a maintenance treatment for adults with newly diagnosed myeloma following an autologous stem-cell transplant as long as patients are put on a 28-day regimen of the drug on a schedule of 10 mg daily for the first three weeks.
NICE has now determined that the drug is cost-effective for such patients after previously deciding not to recommend the drug for use by the NHS. The drug’s list price is $5,172 (£3,780) per pack of 21 capsules, but the company has reached a discount arrangement with the NHS.